Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

230 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Report from the Western Canadian Gastrointestinal Consensus Cancer Conference-Management of Total Neoadjuvant Therapy in Rectal Cancer.
Lim H, Abraham AG, Ahmed S, Ahmed S, Brown CJ, Brunet B, Davies J, Doll C, Dueck DA, Gordon V, Hagel K, Hebbard P, Kim CA, Le D, Lee-Ying R, McGhie JP, Mulder K, Park J, Renouf DJ, Schellenberg D, Wong RPW, Zaidi A. Lim H, et al. Among authors: abraham ag. Curr Oncol. 2022 Feb 8;29(2):924-927. doi: 10.3390/curroncol29020078. Curr Oncol. 2022. PMID: 35200577 Free PMC article.
Long-Term Patient-Reported Quality of Life of Anal Cancer Survivors Treated With Intensity Modulated Radiation Therapy and Concurrent Chemotherapy: Results From a Prospective Phase II Trial.
Joseph K, Balushi MA, Ghosh S, Stenson T, Abraham A, Elangovan A, Warkentin H, Paulson K, Tankel K, Usmani N, Severin D, Schiller D, Wong C, Mulder K, Doll C, King K, Nijjar T. Joseph K, et al. Int J Radiat Oncol Biol Phys. 2023 Oct 1;117(2):434-445. doi: 10.1016/j.ijrobp.2023.04.023. Epub 2023 May 4. Int J Radiat Oncol Biol Phys. 2023. PMID: 37148982 Clinical Trial.
A population-based analysis of the impact of 1 vs. 2 doses of mitomycin on patterns of failure of anal cancer patients treated with concurrent chemoradiotherapy.
Joseph K, Al Habsi Z, Abraham A, Elangovan A, Ghosh S, Pham T, Shreekumar D, Ramji Z, Paulson K, Tankel K, Usmani N, Severin D, Schiller D, Wong C, Mulder K, Karachiwala H, Doll C, King K, Nijjar T. Joseph K, et al. Radiother Oncol. 2024 Mar 12;196:110219. doi: 10.1016/j.radonc.2024.110219. Online ahead of print. Radiother Oncol. 2024. PMID: 38479443
Does Loosening the Inclusion Criteria of the CROSS Trial Impact Outcomes in the Curative-Intent Trimodality Treatment of Oesophageal and Gastroesophageal Cancer Patients?
Abraham AG, Joseph K, Spratlin JL, Zebak S, Alba V, Iafolla M, Ghosh S, Abdelaziz Z, Lui A, Paulson K, Bedard E, Chua N, Tankel K, Koski S, Scarfe A, Severin D, Zhu X, King K, Easaw JC, Mulder KE. Abraham AG, et al. Clin Oncol (R Coll Radiol). 2022 Sep;34(9):e369-e376. doi: 10.1016/j.clon.2022.05.011. Epub 2022 Jun 7. Clin Oncol (R Coll Radiol). 2022. PMID: 35680509 Clinical Trial.
Adjuvant breast radiotherapy, endocrine therapy, or both after breast conserving surgery in older women with low-risk breast cancer: Results from a population-based study.
Joseph K, Zebak S, Alba V, Mah K, Au C, Vos L, Ghosh S, Abraham A, Chafe S, Wiebe E, Liu HW, Chambers C, Gabos Z, Tankel K, Lupichuk S, King K. Joseph K, et al. Radiother Oncol. 2021 Jan;154:93-100. doi: 10.1016/j.radonc.2020.09.017. Epub 2020 Sep 14. Radiother Oncol. 2021. PMID: 32941956
230 results